For immunochemical detection of AROS
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

AROS Polyclonal Antibody (aa 1-50)

Item No. 13496

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • Active Regulator of SIRT1
  • Active Regulator of Sirtuin 1
  • 40S Ribosomal Protein S19-binding Protein 1
  • RPS19-binding Protein 1
  • RPS19BP1
  • S19BP
Immunogen
A synthetic peptide within the region of amino acids 1-50 of human AROS
Formulation (Request formulation change)
100 µg of protein A-affinity purified IgG
Storage Buffer
200 µl PBS with 0.05% BSA and 0.05% sodium azide
Host
Rabbit
Applications
WB
Cross Reactivity
(+) AROS
Species Reactivity
(+) Human
Origin
Animal/Rabbit
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    1 ea

    $370

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Active regulator of SIRT1 (AROS) is a chaperone for ribosomal protein S19 (RPS19) and a modulator of sirtuin 1 (SIRT1) activity.1,2 It is an intrinsically disordered protein that contains localized α-helices.2 AROS is ubiquitously expressed and localizes to the nucleolus and cytoplasm.3,4 It is involved in ribosome biogenesis, specifically the assembly of the small subunit processome where it stabilizes RPS19, and protein synthesis.1,3 AROS activates or inhibits SIRT1 in a context-dependent manner.2,4,5 Methylation of AROS at lysine 27 by histone-lysine N-methyltransferase NSD2 increases the affinity of AROS for SIRT1, which subsequently activates SIRT1 to increase fatty acid β-oxidation in cancer cells.6 Increased expression of RPS19BP1, the gene encoding AROS, is associated with poor prognosis, higher tumor stage and size, microvascular and portal vein invasion, and increased α-fetoprotein levels in patients with non-cirrhotic hepatocellular carcinoma (HCC).7 Cayman’s AROS Polyclonal Antibody (aa 1-50) can be used for Western blot (WB).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Singh, S., and Vanden Broeck, A. Nucleolar maturation of the human small subunit processome. Science 373(6560), eabj5338 (2021).

    2. Weiss, S., Adolph, R.S., Schweimer, K., et al. Molecular mechanism of sirtuin 1 modulation by the AROS protein. Int. J. Mol. Sci. 23(21), 12764 (2022).

    3. Knight, J.R.P., Willis, A.E., and Milner, J. Active regulator of SIRT1 is required for ribosome biogenesis and function. Nucleic Acids Res. 41(7), 4185-4197 (2013).

    4. Kim, E.-J., Kho, J.-H., Kang, M.-R., et al. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell 28(2), 277-290 (2007).

    5. Kokkola, T., Suuronen, T., Molnár, F., et al. AROS has a context-dependent effect on SIRT1. FEBS Lett. 588(9), 1523-1528 (2014).

    6. Li, X., Song, D., Chen, Y., et al. NSD2 methylates AROS to promote SIRT1 activation and regulates fatty acid metabolism-mediated cancer radiotherapy. Cell Rep. 42(10), 113126 (2023).

    7. Kwon, J.-H., Ahn , K.S., Moon, Y.H., et al. AROS is a significant biomarker for tumor aggressiveness in non-cirrhotic hepatocellular carcinoma. J. Korean Med. Sci. 30(9), 1253-1259 (2015).